Yourgene Health and Genetix Launch First Local Non-invasive Prenatal Testing Service in Colombia

Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, has installed the first non-invasive prenatal testing (NIPT) workflow in Colombia at Genetix, a high-tech medical organisation specialised in human genetic diagnosis. Genetix introduced its NipTest at a launch event held in Bogotá, Colombia yesterday evening to raise awareness of this new local NIPT provision to clinicians in the region.

The service will utilise Yourgene’s IONA® Nx NIPT Workflow to deliver fast, accurate NIPT results for expectant parents in Colombia, helping to reduce turnaround times and shipping problems.

Utilising Yourgene’s IONA Nx NIPT Workflow offers Genetix a complete CE-marked in vitro diagnostic (IVD) device to establish its own quality-assured prenatal screening service in-house. The IONA test has been validated on a highly flexible and scalable workflow, suitable for low- to high-volume sample throughput, enabling the growing clinical laboratory to meet rising demands.

The NIPT is performed using cell-free placental DNA from maternal blood to screen for aneuploidies: trisomy 21 (Down’s syndrome), trisomy 18 (Edwards’ syndrome) or trisomy 13 (Patau’s syndrome), and can also be used to determine the sex of the fetus. The analysis is performed using next-generation sequencing technology, with test results available in three days.

Previously, blood samples collected in Colombia were sent to the USA for testing, delaying turnaround times and increasing costs with additional shipping expenses. By offering access to its NipTest locally, Genetix will help to ensure expectant parents receive reliable results quickly, while reducing the need for invasive tests and the associated stress and anxiety.

Lyn Rees, Executive Director, Yourgene Health, said: “We are thrilled to support Genetix by enabling them to deliver an advanced prenatal screening solution locally to the pregnant mothers in Colombia. We look forward to a long and fruitful relationship with their pioneering team.

We are immensely proud, once again, to be contributing to patient care where it is needed. Yourgene is committed to delivering best-in-class NIPT solutions and continues to be a leading player in the global market and a trusted provider.”

Dr Claudia Serrano, General and Scientific Director, Genetix, said: “We are excited to offer this non-invasive test for the first time in Colombia and are delighted to have the backing of our esteemed partners, Yourgene Health.

We strive to advance diagnostic services and transform prenatal genetics in our country and the launch of the NipTest is testament to this. Yourgene’s quality-assured IONA Nx NIPT Workflow empowers us to deliver fast, accurate and reliable NIPT solutions, helping us to improve the lives of our patients and their families.”

For more information about Yourgene’s IONA Nx NIPT Workflow, please visit: https://yourgenehealth.com/our-products/nipt-solutions/nipt/the-iona-test/

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version